IBI-363

From China Leadership to Global Premier: Revenue Surpasses RMB 10 Billion, Entering the Era of Profitability and Globalization SAN FRANCISCO and SUZHOU, China, March 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2025 annual results and long-term strategic blueprint. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "2025 marks the most successful year in Innovent's history. We achieved historic breakthroughs across three areas: business scale, financial strength, and global innovation. We successfully upgraded our strategy from an oncology-focused leader to a 'dual-engine growth model' driven by oncology and general biomedicine portfolio. Encouragingly, we delivered our first full year of net profit, marking a formal entry into an era of sustainable profitability. Our robust cash reserves and positive operating cash flow will provide strong support for strategic growth. On the innovation front, three global high-potential assets advanced into or near global registrational clinical development, targeting a combined addressable market value of over US$60 billion. Meanwhile, we accelerated the global value realization of our pipeline through multiple landmark strategic collaborations, laying a solid foundation for global expansion. Total deal value reached over US$22 billion in the past year, accounting for more than 10% of China's innovative pharmaceutical sector outbound licensing value in 2025[1]. These achievements not only validate the foresight of our strategy but also highlight our uniqueness of strong growth and high certainty within China's biopharma industry. Guided by our Vision 2030 to become a global premier biopharmaceutical company, we will continue to drive progress across four core pillars: revenue, profitability, innovative pipeline and organizational capabilities, creating sustainable value for patients, shareholders and society." Revenue Set New Height, Achieved Full-Year Profitability with Strong Cash Position Total revenue reached RMB 13.0 billion, representing a year-on-year increase of 38.4%. Product revenue amounted to RMB 11.9 billion, up 44.6% year-on-year. From the commercial launch of its first product in 2019 to 18 approved products and surpassing RMB 10 billion revenue milestone, Innovent accomplished this in only 7 years, setting a new growth benchmark for China's innovative biopharmaceutical industry. The Company achieved its first full year of net profit. IFRS net profit reached RMB 814 million, and Non-IFRS net profit rose to RMB 1.72 billion, marking a structural inflection in profitability and entry into a sustainable earnings era. Operating efficiency continued to improve. Gross margin improved 2.3 percentage points to 87.2%. Selling and administrative expense ratio declined 2.9 percentage points to 48.0%. EBITDA surged to RMB 1.99 billion (2024: RMB 412 million). As of December 31, 2025, cash reserves totaled RMB 24.3 billion (~US$3.5 billion). Additionally, the Company also generated positive operating cash flow, providing strong financial support for long-term development. [2] Dual-Engine Strategy Fully Implemented, Commercial Foundation Strengthened China Leading Oncology Brand with Synergistic Value of Innovative Portfolio Innovent has established a leading oncology brand in China. Cornerstone products including TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection) and HALPRYZA® (rituximab injection) have benefited millions of Chinese cancer patients. In addition, five small-molecule targeted oncology drugs—Limertinib (EGFR TKI), DOVBLERON® (Taletrectinib, ROS1i), Dupert® (fulzerasib, KRAS G12Ci), JAYPIRCA® (Pirtobrutinib, BTKi), and Retsevmo® (selpercatinib, RETi) — were successfully included in the 2025 National Reimbursement Drug List (NRDL), further strengthening the competitiveness and commercial performance of Innovent's oncology portfolio. General Biomedicine Franchise Emerged as a New Growth Engine Benefiting from forward-looking strategic layout, Innovent's general biomedicine portfolio delivered strong momentum in 2025. SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025. Within a single year, the general biomedicine portfolio has become a second core engine driving high-speed growth. Today, Innovent possesses one of the highest-quality commercial portfolio and pipeline in the industry, supported by a fully established commercial network, reinforcing its solid commercial foundation. Year of Globalization: Pipeline Value Unlocked, Growth Potential Expanded 2025 marked a breakthrough year for the Company's globalization strategy, unlocking substantial long-term growth potential. Innovent successfully advanced three core assets into or near global Phase 3 clinical trials. According to its partner estimates, these late-stage assets target a combined total addressable market (TAM) of over US$60 billion, including: IBI363 (PD-1/IL-2α-bias): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications In collaboration with Takeda, IBI363 is being advanced globally. The first global MRCT Phase 3 in IO-resistant squamous NSCLC has been initiated. PoC in IO-resistant non-squamous NSCLC is completed, with a new global Phase 3 planned subject to the PoC results and regulatory communications. A Phase 3 trial in 3L colorectal cancer (CRC) in China is planned for 2026. A Phase 2 trial in IO-naïve mucosal/acral melanoma is underway in China. PoC studies in 1L NSCLC and 1L CRC are ongoing. IBI343 (CLDN18.2 ADC): Cornerstone for gastrointestinal cancers, potential TAM over US$8 billion Interim analysis from the China-Japan Phase 3 clinical trial in 3L gastric cancer is expected in 2026. Phase 3 in 3L pancreatic cancer in China was initiated in 2025. PoC studies in 1L gastric and 1L pancreatic cancer are ongoing. IBI324 (VEGF/ANG2): Potential best-in-class retinaltherapy, potential TAM US$15 billion Our partner Ollin Biosciences reported positive top-line results from the Phase 1b JADE head-to-head study against faricimab in wAMD and DME patients in the US. Innovent is working closely with Ollin to engage global regulators in 2026 and advance IBI324 into global Phase 3 trials. Diversified Partnerships to Accelerate Global Innovation Total deal value from Innovent's global collaborations reached over US$22 billion in 2025, representing over 10% of China's innovative pharma outbound licensing value. These partnerships not only accelerate global pipeline development but also help build core capabilities for Innovent to become a truly world-class biopharma. With Takeda: Landmark "IO + ADC" collaboration under a co-development and co-commercialization ("Co-Co") model for IBI363 to build its global R&D and commercialization capabilities. With Eli Lilly: Seventh partnership with an end-to-end innovation model to jointly develop novel oncology and immunology molecules, enhancing full lifecycle R&D frameworks and decision-making from a multinational perspective. With Roche: Leveraging global oncology resources to advance IBI3009 (DLL3 ADC) worldwide. With Ollin: Utilizing global ophthalmology expertise to accelerate IBI324's clinical development and market positioning. High-Quality Manufacturing Standards Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Site 1 houses 60,000 liters of antibody capacity and ADC commercial lines; Site 2 has 80,000 liters of antibody capacity, supporting global supply and CDMO services. Sustainable Development and ESG Commitment 8,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou. Over 3,000 new cancer patients initiate Innovent therapies daily; more than 6 million patients have benefited to date. Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry. First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status). Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management. Published patient education materials on thyroid eye disease and weight management to enhance public health awareness. Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 3.6 billion. Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise". Created over 2,200 jobs for new graduates. Cumulative taxes and contributions exceeding RMB 6 billion. Vision 2030: From China Leader to Global Premier Biopharma Entering 2026, Innovent celebrates its 15th anniversary. Building on its strong foundation, the Company reaffirms Vision 2030: to evolve into a global premier biopharmaceutical company. Revenue: Target RMB 20 billion by 2027 with continued expansion thereafter. International revenue will become a new growth driver in the future. Profitability: Maintain high-quality growth while steadily improving profit margins benchmarking industry-leading levels. Pipeline: Focus on advancing high-value assets including IBI363, IBI343 and IBI324. Push next-generation oncology and general biomedicine molecules into global early-stage and PoC studies. Target at least 5 molecules in global MRCT Phase 3 by 2030. Organization: Established a US R&D and operating team of nearly 100 people. Through deep partnerships with Takeda, Lilly, Ollin, Roche and others, Innovent is rapidly building global R&D, regulatory and commercial capabilities. These growing global competencies will further support independent development, enabling Innovent to leap forward into a fully independent, world-class biopharmaceutical enterprise. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn. Statement: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Ramucirumab (Cyramza)，Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. SOURCE Innovent Biologics 21% more press release views with Request a Demo

“We’re going to end up in a very similar place to 2024 in terms of the volume of deals\" with China biotechs, Evaluate\'s Mark Lansdell told Fierce in early December.\n Despite a year of trade tensions, national security strictures and stark warnings about the U.S.’ waning biotech innovation edge, the fact remains that China is and will likely continue to be a prominent source of innovation for the life sciences industry.Meanwhile, swirling geopolitical pressures and threatened policy changes did little to abate the pace of China biotech acquisition and licensing deals in 2025, and the cumulative value of those accords has never been higher, Mark Lansdell, director, asset and portfolio strategy practice lead at Evaluate, noted in an interview with Fierce Biotech.“We’re going to end up in a very similar place to 2024 in terms of the volume of deals,” Lansdell told Fierce in early December.At the time of the interview, Evaluate had tallied 142 China deals of all types—including licensings, acquisitions and financings—in 2025, according to Lansdell. That marked a slight uptick from the 134 China deals booked in 2024, while remaining largely on par with the volume of overall deals in 2023, he said. In 2022, meanwhile, industry deals with China biotechs reached a high point at 167 agreements for the year. Several more deals have since rolled through in December, such as Bristol Myers Squibb\'s $1.1 billion research pact with Shanghai’s Harbour BioMed, Yarrow Bioscience’s $1.37 billion bid for ex-China rights to a potential first-in-class antibody candidate from a subsidiary of GenSci Pharmaceutical and Formation Bio’s $600 million deal for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals.Meanwhile, just this week, AstraZeneca floated $100 million upfront—plus up to $1.91 billion into potential milestones, as well as royalties—for the rights to a clinical-stage, multitarget asset from China\'s Jacobio Pharma, while Ipsen waded deeper into the antibody-drug conjugate arena with a deal worth up to $1.06 billion for Simcere Zaiming\'s SIM0613, which targets a protein highly expressed on a range of tumor types and cancer-associated fibroblasts. Simcere Zaiming is headquartered in Nanjing.  Crunching numbers with Evaluate For much of the conversation with Fierce, Evaluate’s Lansdell narrowed his focus to licensing and acquisition deals with China-based firms, where similar volume trends have played out in recent years.The pace of deals being struck with Chinese biotechs is “pretty much holding steady” in the present, Lansdell added, noting that he expects that “to continue into 2026.”“I think the interesting thing is value,” he stressed, “because that is where there has been some movement.”Comparing the scope of the deals struck with China biotechs in recent years, the aggregate deal value of 131 licensing or acquisition deals in 2022 was $32.2 billion, Lansdell noted. The total value of those types of deals with China biotechs rose slightly to $35.2 billion in 2023. Then there was then a big jump in 2024 when the total value rose to $51.9 billion. With a month still left to go, the tally was sitting at $92.2 billion in 2025 when Lansdell spoke with Fierce in early December.Lansdell did, however, give the caveat that those figures represent the total potential value of the deals logged—and not necessarily their final realized value.While there have been some “individually very big deals that you perhaps wouldn’t have expected to see three or four years ago,” the “average value has also risen,” Lansdell said, noting that the trend isn’t being driven exclusively by a few high-spending outliers.For context, he noted that the average total potential deal value of pacts with China biotechs in 2022 stood at about $546 million, compared to a “threefold shift” to $1.5 billion in 2025.For an example of a deal trading in that general vicinity, Pfizer hopped onboard the PD-1xVEGF train in May when it handed 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate that puts it in competition with Merck & Co., BioNTech and Summit Therapeutics. As part of the deal, Pfizer has also pledged up to $4.8 billion in milestones for ex-China rights to the drug, coded SSGJ-70. Pfizer is in addition investing $100 million in the China biotech and will pay double-digit royalties on sales of the asset, if approved. Separately, Japan\'s Takeda in October fronted Innovent Biologics $1.2 billion for rights to two cancer assets, tucking in the potential promise of a whopping $10.2 billion in milestones. The Innovent assets, IBI363 and IBI343, have shown promise in treating patients with certain solid tumors. The interplay between volume of deals and total deal values also holds true when looking at the proportion of value coming from industry accords focused on China, Lansdell noted.Whereas China licensing and acquisition agreements constituted some 9% of the total value of industry deals in 2022, that figure had risen substantially to 21% by the end of November 2025.“That is becoming quite significant,” Lansdell said.Lansdell explained that much of the value of those deals is backloaded into potential milestones and royalties, with the lower relative value of the upfront payments both \"pretty attractive\" for the dealmakers and potentially signaling a certain degree of prudence when striking deals with China biotechs.\"There\'s not that overexuberance there in the way that there is for the potential total deal values,\" Lansdell said, referring to the upfront payments in the deals Evaluate tallied. At this point, China’s R&D output is likely too prolific to ignore, said Lansdell, who noted that companies—especially those playing in modalities like ADCs, bispecifics or cell therapies—“would actively need to be looking away from China” to avoid striking deals with biotechs there.“China has been very smart in picking the right modalities, the right disease and therapy areas,” Landsell pointed out. The lay of the land Lansdell is far from the only industry watcher to highlight China’s growing influence on the innovative biopharma landscape.Back in July, analysts at Jefferies noted that in the first three months of 2025, 32% of outlicensing biotech deal value stemmed from China, versus 21% reported in both 2024 and 2023.“We believe China biotechs are reshaping the U.S. biopharma landscape, as in-licensing assets from China could offer multinational corporations a remedy to alleviate pressure affordably and within a manageable time frame,” the analysts wrote in a note to clients this summer.Still, not everyone feels comfortable with China\'s increasing sway in the industry, with PwC analysts warning earlier this year that the swift evolution of the country’s biotech sector has created “heightened risks related to IP security, regulatory compliance and strategic alignment.”While near-term prospects for China biotech M&A remained “robust” at 2025’s midyear mark, according to PwC, the professional services group warned that emerging “multifaceted regulatory and geopolitical set of challenges” meant companies need “comprehensive due diligence and strategic foresight” in their dealmaking.“The sector’s focus remains on bespoke bolt-on deals to strategically strengthen innovation pipelines amid an increasingly complex regulatory environment,” Roel van den Akker, U.S. pharma and life sciences deals leader at PwC, said in a statement at the time.Adding another potential wrinkle to the industry’s work with China is the Biosecure Act, a piece of China-targeting national security legislation that failed to make the cut in 2024 but recently passed through both the House and Senate as part of the U.S. annual defense spending bill.In essence, the legislation prevents executive U.S. agencies from working with “biotechnology companies of concern” for equipment or services and, critically, the prohibition extends to federal contracts with drugmakers that would involve using equipment and services from those targeted companies.That said, the bill has been defanged in many ways from the original incarnation introduced in early 2024. Whereas the previous draft named five companies directly—sparking backlash—the new bill changes the approach by tapping the Office of Management and Budget with coming up with a list of relevant companies \"of concern\" while also utilizing the Pentagon\'s Section 1260H list of firms associated with the Chinese military. In a sit-down with Fierce Biotech this past fall, Paul Hastings, CEO of Nkarta and former chair of the Biotechnology Innovation Organization, acknowledged the importance of measures to reduce U.S. dependence on foreign countries like Biosecure.But, at the same time, in terms of innovation coming out of China, Hastings urged the federal government to “let that one go.”“We can then make that innovation U.S.-led,” Hastings told Fierce  in October. “Because when you license something, it becomes yours.“Don\'t punish someone because they\'ve licensed a Chinese asset,” Hastings continued.